In terms of chemical therapy, ARHGAP5-AS1 was identified as an upregulated lncRNA in chemo-resistant GC cells that stabilizes ARHGAP5 mRNA by promoting m6A modification of ARHGAP5 mRNA through recruitment of METTL3.[93] The upregulation of ARHGAP5 promotes chemotherapy resistance and predicts a poor prognosis in GC.[93] Oxaliplatin is the first-line treatment for advanced GC,[151] and poly (ADP-ribose) polymerase 1 (PARP1) is the crucial gene generating oxaliplatin-resistant hallmarks in CD133+ GC stem cells by efficiently repairing DNA damage caused by oxaliplatin. Here, ARHGAP5 is linked to gastric cancer.